focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Q: Can we say how long we’ve been in discussion with the potential new big pharmaceutical client?
We’ve been in discussion with them for over 12 months, and that is common for big pharma clients.
Large pharma been in discussions 12 months prior to March 2022 interims news due
From the interims.. In addition to the areas noted above, the Company is actively considering how it could use its extensive capabilities in modelling, simulation, data analysis and AI techniques, to develop further innovative assets in collaboration with other partners. The Company is particularly focused on fields such as AI-enabled drug discovery/development and cancer diagnostics. Further information on this initiative will be provided as progress is made.
It won't take a lot too move this up nicely!
Another £1600 in JISA
£5k is 5p
£2.5k 4.8p
£15k 5.2p
I wonder if PYC still have some license agreement with the work they did on sra737 ?
Added another 67,787
Very much so, you would think with the 2 year backlog due to covid, things can only be helped / improved / solved by A.I and drug development.
So GSK buy Sierra Oncology - hmmmmm - links ;-)
There is definitely a different feel to this company in the last two or three years or so. The day to day contract stuff is rising and we have three longer term commercial trials/contracts on the go. I guess the most obvious to increase revenue is the VAL one. I think the company has done well to keep the cost base down in spite of the rising headcount and have just done a small 1K top- up to benefit from the rising SP as revenue starts to rise and inevitably profits will follow.
Added another 106128 shares.. Really pleased to have got £10k down at these prices !!
Shame your noise seems to have ticked us up, I'm adding another £5k this morning
Since 2016 the company has been transformed from a company with revenues under a million which doesn't make a profit into a company with revenues under a million which doesn't make a profit.
Also check out who works with our recent repeat client Numab
Company has also signed on Numab Therapeutics this year. Numab is a well-funded biotech operating in various therapy areas including oncology and boasts Daniel Vasella, the former CEO of Novartis, as its Chairman.
I think GSK as be the large pharma as CEO was business development there for 15yrs prior to becoming CEO in 2016, he has transformed PYC since 2016 hence why the 20yrs rubbish from share4 is laughable
Jim is taking us to profitability unlike the mgmt PRIOR to 2016
Good spot 1978
https://www.investegate.co.uk/physiomics-plc--pyc-/rns/final-results/201710160700036079T/
Yes, it was 2017, but "Received payments from Sareum for modelling carried out in 2010 to support the identification of an optimal combination regime of a Chk1 inhibitor and a DNA-damaging agent following the licensing of a compound in this family to ProNAi Therapeutics (now Sierra Oncology)"
GSK acquire Sierra. SAR did deal with Sierra and PYC work(Ed) with SAR https://www.londonstockexchange.com/news-article/GSK/gsk-agrees-to-acquire-sierra-oncology-for-1-9bn/15410539
Pleased to see you are still here, hope you on the road to recovering after your medical issue. ATB.
It's quite all right share4 - no need to apologise for not understanding my post.
Admin.. ~2765GH
Truro, yes I know it's a guess, but as I said the company is giving no visibility on this, so answer the question. They are quite happy to announce "record revs" which don't need to be above a million after 20 years which is pretty embarrassing stuff, so I would think that if they were confident on making a profit next year they'd be shouting it from the rooftops wouldn't they? Wouldn't a company hat feels it is going to be profitable look for broker coverage?
Also, please refrain from making personal attacks on posters. If you are confident about this share there is no reason you can't present your logical thought process.
Truro - Just report the poster - They've admitted they don't hold so are just disruptive to the board and have mocked mental health.
Re-read my post share4 and then comprehend it. You ask nonsensical and foolish questions. You might need to look up 'guess' in a dictionary.